ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Eric Karas sold 10,000 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now directly owns 5,693 shares of the company’s stock, valued at approximately $79,702. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
ARS Pharmaceuticals Price Performance
ARS Pharmaceuticals stock traded up $0.24 during mid-day trading on Monday, hitting $13.20. The company’s stock had a trading volume of 876,687 shares, compared to its average volume of 715,928. The business has a 50 day moving average price of $10.43 and a 200-day moving average price of $9.36. ARS Pharmaceuticals, Inc. has a 12 month low of $2.55 and a 12 month high of $16.50. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -24.92 and a beta of 0.87.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of analysts have recently issued reports on the stock. Leerink Partners lifted their price objective on shares of ARS Pharmaceuticals from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Cantor Fitzgerald initiated coverage on ARS Pharmaceuticals in a report on Tuesday, August 20th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Raymond James raised ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $22.75.
Read Our Latest Stock Analysis on ARS Pharmaceuticals
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Featured Stories
- Five stocks we like better than ARS Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Investing in Commodities: What Are They? How to Invest in Them
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.